Lazard Asset Management’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-183,991
Closed -$2.51M 2323
2024
Q1
$2.51M Hold
183,991
﹤0.01% 802
2023
Q4
$2.48M Hold
183,991
﹤0.01% 811
2023
Q3
$2.29M Sell
183,991
-1,341
-0.7% -$17.6K ﹤0.01% 850
2023
Q2
$2.51M Hold
185,332
﹤0.01% 847
2023
Q1
$2.58M Hold
185,332
﹤0.01% 868
2022
Q4
$2.63M Hold
185,332
﹤0.01% 861
2022
Q3
$2.53M Hold
185,332
﹤0.01% 835
2022
Q2
$2.64M Hold
185,332
﹤0.01% 853
2022
Q1
$3.06M Hold
185,332
﹤0.01% 828
2021
Q4
$3.56M Hold
185,332
﹤0.01% 838
2021
Q3
$3.85M Sell
185,332
-19,130
-9% -$409K ﹤0.01% 813
2021
Q2
$4.38M Hold
204,462
﹤0.01% 741
2021
Q1
$4.03M Hold
204,462
﹤0.01% 698
2020
Q4
$4.04M Hold
204,462
0.01% 684
2020
Q3
$3.59M Buy
204,462
+11,892
+6% +$213K 0.01% 651
2020
Q2
$3.46M Buy
192,570
+148,525
+337% +$2.55M 0.01% 615
2020
Q1
$659K Buy
+44,045
New +$721K ﹤0.01% 781
2014
Q1
Sell
-149,729
Closed -$3.06M 1034
2013
Q4
$3.06M Hold
149,729
0.01% 573
2013
Q3
$2.88M Sell
149,729
-887
-0.6% -$17K 0.01% 569
2013
Q2
$2.68M Buy
+150,616
New +$2.72M 0.01% 594

Other funds holding HQL

Lazard Asset Management's HQL Position: Q2 2024 in Review

Lazard Asset Management sold out of abrdn Life Sciences Investors (HQL) in Q2 2024, closing a stake of 183,991 shares — an estimated $2.51M sold.

Lazard Asset Management first reported a position in HQL in Q2 2013 and held it in 20 quarters. The position peaked at $4.38M in Q2 2021. 75 funds tracked by Wall St. Rank hold HQL as of Q2 2024.

  • Lazard Asset Management reported no remaining abrdn Life Sciences Investors position as of Q2 2024 after selling out during the quarter.
  • Lazard Asset Management sold 183,991 abrdn Life Sciences Investors shares in Q2 2024, an estimated $2.51M.
  • Lazard Asset Management first reported a position in abrdn Life Sciences Investors in Q2 2013 and held it in 20 quarters.
  • Lazard Asset Management's abrdn Life Sciences Investors position peaked at $4.38M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.